DGX reports second-quarter results on July 21 with options traders striking their most defensive posture in months — even as short sellers quietly retreat from the name.
The clearest pre-earnings signal is in the options market. The put/call ratio jumped to 0.86 on Thursday, more than two standard deviations above its 20-day average of 0.71 — the most elevated defensive reading in recent weeks. That's a notable shift for a stock that has traded with relatively muted hedging demand through most of June. At the same time, the stock has drifted quietly higher, gaining nearly 5% over the past month to close at $210.68, adding 1.6% on the week. The borrow market tells a straightforwardly relaxed story: availability runs above 1,000% of short interest, meaning shares to lend vastly outnumber shares already borrowed, and cost to borrow has eased roughly 9% over the week to just 0.49% — about as cheap as it gets.
Short interest is a secondary signal here, not a primary one. Bears hold about 3.8% of the free float short — a moderate level — but the trend has turned against them sharply. SI fell 14% over the past week after peaking near 4.9 million shares on July 8. That pullback suggests some short sellers already moved ahead of the print rather than pressing the position into it.
The analyst community is broadly sidelined but nudging targets higher. Baird lifted its price target to $236 just five days ago while keeping a Neutral rating — a pattern visible across most of the recent coverage, with UBS and Barclays also raising targets after the Q1 beat in April without upgrading their ratings. The mean target of $224 implies roughly 6% upside from current levels. Bulls point to accelerating consumer-initiated testing revenue — up 35% year-over-year and approaching $250 million — and the broader volume recovery in advanced diagnostics. Bears flag softening revenue per requisition and the loss of volume from Corewell and Fresenius, which dragged the average ticket below expectations last quarter. The PE has expanded to 18.6x on a trailing basis, up nearly a full turn over the past month, so the stock is no longer cheap by its own recent standards. The dividend factor score ranks in the 98th percentile, anchoring the thesis for income-focused holders.
After the April print, DGX jumped nearly 4% on the day before fading to essentially flat over the following five sessions — the setup this quarter is similar in that the stock has already moved before the report. Closest peer LH has gained 2.4% on the week, tracking DGX closely, while GH and SGRY have both slipped around 2.5%, suggesting the diagnostics tailwind is specific to the larger-cap names rather than sector-wide. The July 21 print will test whether the volume recovery and consumer-testing momentum are durable enough to justify both the recent re-rating and the unusual spike in put demand heading into the number.
See the live data behind this article on ORTEX.
Open DGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
